Stock Track | TG Therapeutics Plunges 9% Pre-Market Despite Meeting Q3 Estimates

Stock Track11-04 20:04

Shares of TG Therapeutics (NASDAQ: TGTX) were down over 9% in pre-market trading on Friday, despite the company reporting third-quarter earnings and revenue that met or exceeded analyst expectations.

For the third quarter of 2024, TG Therapeutics reported earnings per share of $0.02, meeting the consensus estimate from analysts. However, this represented a staggering 97.26% decrease from the earnings of $0.73 per share in the same period last year.

The company's quarterly revenue of $83.88 million beat the analyst consensus estimate of $81.71 million by 2.66%. Nevertheless, this revenue figure also marked a significant 49.41% decline compared to the $165.81 million in revenue recorded in the third quarter of 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199500872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199500872","market":"hk","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Plunges 9% Pre-Market Despite Meeting Q3 Estimates","media":"Stock Track","content":"<p>Shares of TG Therapeutics (NASDAQ: TGTX) were down over 9% in pre-market trading on Friday, despite the company reporting third-quarter earnings and revenue that met or exceeded analyst expectations.</p>\n\n<p>For the third quarter of 2024, TG Therapeutics reported earnings per share of $0.02, meeting the consensus estimate from analysts. However, this represented a staggering 97.26% decrease from the earnings of $0.73 per share in the same period last year.</p>\n\n<p>The company's quarterly revenue of $83.88 million beat the analyst consensus estimate of $81.71 million by 2.66%. Nevertheless, this revenue figure also marked a significant 49.41% decline compared to the $165.81 million in revenue recorded in the third quarter of 2023.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Plunges 9% Pre-Market Despite Meeting Q3 Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Plunges 9% Pre-Market Despite Meeting Q3 Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 20:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of TG Therapeutics (NASDAQ: TGTX) were down over 9% in pre-market trading on Friday, despite the company reporting third-quarter earnings and revenue that met or exceeded analyst expectations.\n...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1199500872","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199500872","pubTimestamp":1730721853,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of TG Therapeutics  were down over 9% in pre-market trading on Friday, despite the company reporting third-quarter earnings and revenue that met or exceeded analyst expectations.For the third quarter of 2024, TG Therapeutics reported earnings per share of $0.02, meeting the consensus estimate from analysts. However, this represented a staggering 97.26% decrease from the earnings of $0.73 per share in the same period last year.The company's quarterly revenue of $83.88 million beat the anal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"尽管达到第三季度预期，TG Therapeutics股价盘前暴跌9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"Shares of TG Therapeutics (NASDAQ: TGTX) were down over 9% in pre-market trading on Friday, despite the company reporting third-quarter earnings and revenue that met or exceeded analyst expectations.\nFor the third quarter of 2024, TG Therapeutics reported earnings per share of $0.02, meeting the consensus estimate from analysts. However, this represented a staggering 97.26% decrease from the earnings of $0.73 per share in the same period last year.\nThe company's quarterly revenue of $83.88 million beat the analyst consensus estimate of $81.71 million by 2.66%. Nevertheless, this revenue figure also marked a significant 49.41% decline compared to the $165.81 million in revenue recorded in the third quarter of 2023.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199500872"}